Intersection of http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution and http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution

This is the CodeSystem that contains codes in both Substance Admin Substitution (http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution) and Substance Admin Substitution (http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution).

Structure

Generated Narrative: CodeSystem 5127f8b7-6ff3-42d1-85bd-471f7469a43a-3567

Properties

This code system defines the following properties for its concepts

NameCodeURITypeDescription
SpecializesSpecializesCodingThe child code is a more narrow version of the concept represented by the parent code. I.e. Every child concept is also a valid parent concept. Used to allow determination of subsumption. Must be transitive, irreflexive, antisymmetric.
GeneralizesGeneralizesCodingInverse of Specializes. Only included as a derived relationship.
internalIdinternalIdhttp://terminology.hl7.org/CodeSystem/utg-concept-properties#v3-internal-idcodeThe internal identifier for the concept in the HL7 Access database repository.
Not SelectablenotSelectablehttp://hl7.org/fhir/concept-properties#notSelectablebooleanIndicates that the code is abstract - only intended to be used as a selector for other concepts
Statusstatushttp://hl7.org/fhir/concept-properties#statuscodeDesignation of a concept's state. Normally is not populated unless the state is retired.
SpecializesSpecializesCodingThe child code is a more narrow version of the concept represented by the parent code. I.e. Every child concept is also a valid parent concept. Used to allow determination of subsumption. Must be transitive, irreflexive, antisymmetric.
GeneralizesGeneralizesCodingInverse of Specializes. Only included as a derived relationship.
internalIdinternalIdhttp://terminology.hl7.org/CodeSystem/utg-concept-properties#v3-internal-idcodeThe internal identifier for the concept in the HL7 Access database repository.
Not SelectablenotSelectablehttp://hl7.org/fhir/concept-properties#notSelectablebooleanIndicates that the code is abstract - only intended to be used as a selector for other concepts
Statusstatushttp://hl7.org/fhir/concept-properties#statuscodeDesignation of a concept's state. Normally is not populated unless the state is retired.

Concepts

This code system http://hl7.org/fhir/comparison/CodeSystem/5127f8b7-6ff3-42d1-85bd-471f7469a43a-3567 defines codes in an undefined hierarchy, but no codes are represented here

LvlCodeDisplayDefinitioninternalIdNot SelectableStatusinternalIdNot SelectableStatus
1_ActSubstanceAdminSubstitutionCode ActSubstanceAdminSubstitutionCode

Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects.

21284, 21284true, trueactive, active21284, 21284true, trueactive, active
2  E equivalent

Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.

23107active23107active
3    EC equivalent composition

Substitution occurred or is permitted with another product that is a:

  • pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester
  • pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration

Examples:

  • Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate
  • Pharmaceutical equivalent: Lisonpril for Zestril
23108active23108active
4      BC brand composition

Substitution occurred or is permitted between equivalent Brands but not Generics

Examples:

  • Zestril for Prinivil
  • Coumadin for Jantoven
23109active23109active
4      G generic composition

Substitution occurred or is permitted between equivalent Generics but not Brands

Examples:

  • Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)
16623active16623active
3    TE therapeutic alternative

Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile.

Examples:

  • ranitidine for Tagamet
16624active16624active
4      TB therapeutic brand

Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics

Examples:

  • Zantac for Tagamet
23105active23105active
4      TG therapeutic generic

Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands

Examples:

  • Ranitidine for cimetidine
23106active23106active
2  F formulary

This substitution was performed or is permitted based on formulary guidelines.

16625active16625active
2  N none

No substitution occurred or is permitted.

16622active16622active
2  E equivalent

Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.

23107, 23107active, active23107, 23107active, active
3    EC equivalent composition

Substitution occurred or is permitted with another product that is a:

  • pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester
  • pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration

Examples:

  • Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate
  • Pharmaceutical equivalent: Lisonpril for Zestril
23108active23108active
4      BC brand composition

Substitution occurred or is permitted between equivalent Brands but not Generics

Examples:

  • Zestril for Prinivil
  • Coumadin for Jantoven
23109active23109active
4      G generic composition

Substitution occurred or is permitted between equivalent Generics but not Brands

Examples:

  • Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)
16623active16623active
3    TE therapeutic alternative

Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile.

Examples:

  • ranitidine for Tagamet
16624active16624active
4      TB therapeutic brand

Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics

Examples:

  • Zantac for Tagamet
23105active23105active
4      TG therapeutic generic

Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands

Examples:

  • Ranitidine for cimetidine
23106active23106active
3    EC equivalent composition

Substitution occurred or is permitted with another product that is a:

  • pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester
  • pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration

Examples:

  • Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate
  • Pharmaceutical equivalent: Lisonpril for Zestril
23108, 23108active, active23108, 23108active, active
4      BC brand composition

Substitution occurred or is permitted between equivalent Brands but not Generics

Examples:

  • Zestril for Prinivil
  • Coumadin for Jantoven
23109active23109active
4      G generic composition

Substitution occurred or is permitted between equivalent Generics but not Brands

Examples:

  • Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)
16623active16623active
4      BC brand composition

Substitution occurred or is permitted between equivalent Brands but not Generics

Examples:

  • Zestril for Prinivil
  • Coumadin for Jantoven
23109, 23109active, active23109, 23109active, active
4      G generic composition

Substitution occurred or is permitted between equivalent Generics but not Brands

Examples:

  • Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)
16623, 16623active, active16623, 16623active, active
3    TE therapeutic alternative

Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile.

Examples:

  • ranitidine for Tagamet
16624, 16624active, active16624, 16624active, active
4      TB therapeutic brand

Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics

Examples:

  • Zantac for Tagamet
23105active23105active
4      TG therapeutic generic

Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands

Examples:

  • Ranitidine for cimetidine
23106active23106active
4      TB therapeutic brand

Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics

Examples:

  • Zantac for Tagamet
23105, 23105active, active23105, 23105active, active
4      TG therapeutic generic

Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands

Examples:

  • Ranitidine for cimetidine
23106, 23106active, active23106, 23106active, active
2  F formulary

This substitution was performed or is permitted based on formulary guidelines.

16625, 16625active, active16625, 16625active, active
2  N none

No substitution occurred or is permitted.

16622, 16622active, active16622, 16622active, active